BR112013016661A2 - emulsões de o/a compreendendo alcanos semifluorados - Google Patents

emulsões de o/a compreendendo alcanos semifluorados

Info

Publication number
BR112013016661A2
BR112013016661A2 BR112013016661A BR112013016661A BR112013016661A2 BR 112013016661 A2 BR112013016661 A2 BR 112013016661A2 BR 112013016661 A BR112013016661 A BR 112013016661A BR 112013016661 A BR112013016661 A BR 112013016661A BR 112013016661 A2 BR112013016661 A2 BR 112013016661A2
Authority
BR
Brazil
Prior art keywords
emulsions
semifluorinated
semifluorinated alkanes
alkane
compositions
Prior art date
Application number
BR112013016661A
Other languages
English (en)
Other versions
BR112013016661B1 (pt
Inventor
Bastian Theisinger
Bernhard Gunther
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of BR112013016661A2 publication Critical patent/BR112013016661A2/pt
Publication of BR112013016661B1 publication Critical patent/BR112013016661B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

emulsões de o/a compreendendo alcanos semifluorados a invenção fornece composições líquidas na forma de emulsões fisicamente estáveis compreendendo um alcano semifluorado. o alcano semiflourado é compreendido na fase que pode incluir também um ingrediente farmacêutico ativo. um dos ingredientes ativos preferidos é propofol. as composições são opcionalmente esterillizáveis a calor e podem ser utilizadas para aplicações de produto cosmético ou farmacêutico, e administrado topicamente, por via intravenosa ou através de outras vias.
BR112013016661-4A 2011-01-04 2012-01-03 Emulsões de o/a compreendendo alcanos semifluorados BR112013016661B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11150064 2011-01-04
EP11150064.1 2011-01-04
PCT/EP2012/050043 WO2012093113A1 (en) 2011-01-04 2012-01-03 O/w-emulsions comprising semifluorinated alkanes

Publications (2)

Publication Number Publication Date
BR112013016661A2 true BR112013016661A2 (pt) 2016-10-04
BR112013016661B1 BR112013016661B1 (pt) 2021-08-03

Family

ID=43978091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016661-4A BR112013016661B1 (pt) 2011-01-04 2012-01-03 Emulsões de o/a compreendendo alcanos semifluorados

Country Status (15)

Country Link
US (5) US20140004197A1 (pt)
EP (2) EP3202421B1 (pt)
JP (1) JP6073244B2 (pt)
KR (1) KR101910213B1 (pt)
CN (1) CN103313729B (pt)
AU (1) AU2012204932B2 (pt)
BR (1) BR112013016661B1 (pt)
CA (1) CA2819988C (pt)
DK (2) DK2661280T3 (pt)
ES (2) ES2675242T3 (pt)
MX (1) MX353154B (pt)
PL (2) PL3202421T3 (pt)
PT (2) PT2661280T (pt)
TR (2) TR201901309T4 (pt)
WO (1) WO2012093113A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012160180A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
PT3192501T (pt) 2011-05-25 2020-07-31 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
BR112014017719A8 (pt) 2012-01-23 2017-07-11 Novaliq Gmbh Composições de proteína estabilizada baseadas em alcanos semifluorados
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
CN113679698B (zh) 2012-09-12 2022-07-26 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
GB2511028A (en) * 2012-12-18 2014-08-27 Univ Manchester Metropolitan Nano emulsions, methods of forming the same and uses thereof
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
CN112641720A (zh) * 2014-03-03 2021-04-13 诺华股份有限公司 硫辛酸胆碱酯组合物及使用方法
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
ES2803248T3 (es) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexil octano para administración oftálmica
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
PL3856128T3 (pl) 2018-09-27 2023-10-16 Dermaliq Therapeutics, Inc. Formulacja filtra przeciwsłonecznego do stosowania miejscowego
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache
FR3112475B1 (fr) 2020-07-20 2023-11-10 Naos Inst Of Life Science formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires
AU2021426502A1 (en) * 2021-02-05 2023-08-17 Epalex Corporation Fospropofol methods and compositions
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
WO2005051305A2 (en) * 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
EP1922060B1 (en) 2005-08-05 2009-01-14 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
PL2661280T3 (pl) 2019-05-31
EP3202421B1 (en) 2018-03-28
US20200360285A1 (en) 2020-11-19
TR201901309T4 (tr) 2019-02-21
KR20140003477A (ko) 2014-01-09
CN103313729A (zh) 2013-09-18
PT3202421T (pt) 2018-07-03
PT2661280T (pt) 2019-02-25
CA2819988C (en) 2019-11-12
US20230139672A1 (en) 2023-05-04
EP3202421A1 (en) 2017-08-09
JP6073244B2 (ja) 2017-02-01
EP2661280A1 (en) 2013-11-13
DK3202421T3 (en) 2018-07-16
WO2012093113A1 (en) 2012-07-12
DK2661280T3 (en) 2019-03-04
CA2819988A1 (en) 2012-07-12
US20170216204A1 (en) 2017-08-03
CN103313729B (zh) 2016-11-09
JP2014501270A (ja) 2014-01-20
TR201808752T4 (tr) 2018-07-23
MX2013007807A (es) 2013-12-16
KR101910213B1 (ko) 2018-12-19
MX353154B (es) 2017-12-20
EP2661280B1 (en) 2018-11-21
US20140004197A1 (en) 2014-01-02
AU2012204932B2 (en) 2017-02-23
BR112013016661B1 (pt) 2021-08-03
ES2675242T3 (es) 2018-07-09
AU2012204932A1 (en) 2013-07-04
PL3202421T3 (pl) 2018-10-31
ES2711760T3 (es) 2019-05-07
US20190224123A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
BR112013016661A2 (pt) emulsões de o/a compreendendo alcanos semifluorados
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
WO2012160179A3 (en) Topical pharmaceutical composition based on semifluorinated alkanes
UY31631A1 (es) Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112015007083A2 (pt) inibidores de histona demetilases
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
DOP2013000300A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BR112015011430A2 (pt) composição para liberação imediata e prolongada
DOP2015000170A (es) Compuestos químicos
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
CO6710926A2 (es) Compuestos de n-heteroarilo
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
BR112013017570A2 (pt) compostos de pirazola como antagonistas de crth2
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
BR112015014367A2 (pt) formulações inibidoras de lfa-1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/01/2012, OBSERVADAS AS CONDICOES LEGAIS.